UK-based Ergomed, dedicated to the provision of services for developing new drugs, has appointed Andrew Mackie as chief business officer and to its board as executive director. Read more


Aeterna Zentaris has selected Ergomed to manage the confirmatory Phase 3 clinical study demonstrating the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency. Read more


Ergomed plc, a UK based company dedicated to the provision of specialised services to the pharmaceutical industry, has announced it has made the strategic acquisition of Sound Opinion. Read more


Drug development services company Ergomed has appointed Rolf Stahel to its board as non-executive chairman. Stahel brings over 30 years’ experience in the global pharmaceutical industry. Read more